• 1
    Partridge AH, Winer EP. Informing clinical trial participants about study results. JAMA. 2002; 288: 363365.
  • 2
    Federal policy for the protection of human subjects. Final rule. Fed Regist. 1991; 56: 2800328018 [codified in: Department of Health and Human Services. Code of federal regulations. Title 45, Section 46].
  • 3
    Bell J, Brady M, Lage J, et al. A randomized Phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group study [abstract]. Gynecol Oncol. 2003; 88: 156.
  • 4
    Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003; 95: 125132.
  • 5
    Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95: 113125.
  • 6
    Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003; 95: 105112.
  • 7
    Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol. 2003; 21: 298305.